Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
FibroBiologics, Inc.
FibroBiologics Announces Pricing of $3 Million Public Offering
March 31, 2026
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
March 31, 2026
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
March 25, 2026
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
March 12, 2026
←
Previous Page
1
2